enVista Hydrophobic Acrylic Intraocular Lens (IOL); enVista Hydrophobic Acrylic Intraocular Lens
Bausch + Lomb, Inc. · Decision date Jul 22, 2026
What did the FDA decide?
FDA records P910056/S062 as a supplement to PMA P910056, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jul 22, 2026.
FDA approval order statement
a change to the Refractive Index Test Instrument (refractometer)
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Ophthalmic
- Decision date
- Jul 22, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P910056/S062
- Regulatory pathway
- PMA supplement
- Applicant
- Bausch + Lomb, Inc.
- Product code
- HQL
- Decision code
- OK30
- Decision date
- Jul 22, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: intraocular lens.
- Applicant
- Bausch + Lomb, Inc.
- Product code
- HQL
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P910056. Subsequent supplements may change the device or its indications.
FDA decision timeline
P910056 · Original PMA
SOFLEX UV-ABSORBING SILICONE POSTERIOR CHAMBER INTRAOCULAR LENS
P910056/S062 received
Application receipt date recorded by FDA.
P910056/S062 · FDA decision
30-Day Notice
P910056/S063 · Related supplement
enVista hydrophobic acrylic intraocular lens
P910056/S065 · Related supplement
enVista Aspire Hydrophobic Acrylic Intraocular Lens (IOL)
P910056/S064 · Related supplement
enVista Hydrophobic Acrylic Intraocular Lens
P910056/S066 · Related supplement
enVista Hydrophobic Acrylic Intraocular Lens
P910056/S067 · Related supplement
enVista Hydrophobic Acrylic Intraocular Lens
Timeline entries are records held by MedtechLedger for P910056. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P910056
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Bausch + Lomb, Inc. | PMA approval | Jan 17, 1992 | FDA | |
enVista hydrophobic acrylic intraocular lensP910056/S063 | Bausch + Lomb, Inc. | PMA supplement | Sep 3, 2026 | FDA |
| Bausch + Lomb, Inc. | PMA supplement | Sep 29, 2026 | FDA | |
enVista Hydrophobic Acrylic Intraocular LensP910056/S064 | Bausch + Lomb, Inc. | PMA supplement | Sep 30, 2026 | FDA |
enVista Hydrophobic Acrylic Intraocular LensP910056/S066 | Bausch + Lomb, Inc. | PMA supplement | Oct 14, 2026 | FDA |
enVista Hydrophobic Acrylic Intraocular LensP910056/S067 | Bausch + Lomb, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Explore the linked device profile
Other records with product code HQL
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
FINEVISION HP Trifocal IOLsP240038/S004 | Beaver-Visitec International, Inc. | PMA supplement | Oct 27, 2026 | FDA |
CT LUCIA Intraocular Lenses (IOLs)P100016/S028 | Carl Zeiss Meditec Production, LLC | PMA supplement | Oct 23, 2026 | FDA |
| Johnson & Johnson Surgical Vision, Inc. | PMA supplement | Oct 19, 2026 | FDA | |
| Johnson & Johnson Surgical Vision, Inc. | PMA supplement | Oct 19, 2026 | FDA | |
FINEVISION HP Trifocal IOLsP240038/S003 | Beaver-Visitec International, Inc. | PMA supplement | Sep 25, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Bausch + Lomb, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 50 Technology Dr., Irvine, CA, 92618
Sources and methodology
- Original FDA record: P910056/S062
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





